Liliana López

Liliana López

Auto-generated profile, based on publicly available information

Liliana López

Grupo de Investigación Clínica PECET, GIC-PECET, Universidad de Antioquia, Colombia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LLLiliana López
Liliana López
IVIván Vélez
Iván Vélez
CAClaudia Asela
Claudia Asela
CCClaudia Cruz
Claudia Cruz
FAFabiana Alves
Fabiana Alves
BAByron Arana
Byron Arana
Pentavalent antimonials (Sb5) are the first-line drugs for treating cutaneous leishmaniasis in Colombia; however, given problems with toxicity, compliance, availability, and cost, it is imperative to look for better therapeutic options. Intravenous amphotericin B (AmB) has been used extensively to treat visceral leishmaniasis; however, evidence on its topical use for cutaneous leishmaniasis is limited. Anfoleish is a topical formulation based on 3% AmB, which was developed following GMP standards by HUMAX and PECET. Anfoleish was shown to be safe and efficacious in animal model and in an open label study in CL patients. Hereafter we show the results of the first controlled and randomized study assessing the safety and efficacy of Anfoleish administered topically, two or three times per day for 28 days, for the treatment of non-complicated cutaneous leishmaniasis in Colombia. An open-label, randomized, non-comparative phase Ib/II clinical trial was performed. Adult volunteers with a parasitologically confirmed diagnosis of cutaneous leishmaniasis were randomly allocated to receive Anfoleish cream either 3 (TID group) or 2 (BID group) times per day for 4 weeks. 80 out of 105 subjects screened were included in the study. In intention to treat analysis, final cure was observed in 13 (32.5%) out of 40 subjects (IC 95% = 20.1–48) and in 12 (30%) out of 40 subjects (IC 95% = 18.1–45.5) in the BID and TID group respectively. In the per protocol analysis, cure rates were 39.4% (n = 13) (IC 95% = 24.7–56.3) and 35.3% (n = 12) (IC 95% = 21.5–52.1) in the BID and TID groups respectively. Anfoleish proved to be safe, and the few adverse events reported were local, around the area of application of the cream, and of mild intensity. Anfoleish showed to be a safe and well-tolerated intervention. Its efficacy results however do not support at this time continuing with its clinical development or recommending it for the treatment of CL. Additional, studies to improve its current formulation are needed before thinking in conducting additional studies in patients. Registered in clinicaltrials.gov NCT01845727. Cutaneous leishmaniasis is a disease caused by Leishmania parasites and transmitted by sand flies. It is a complex disease and is underresearched disease, that depending on the parasite species, can take multiple forms, which can be less or more aggressive. It manifests as ulcers, nodules or other lesions mostly on the face and extremities. Cutaneous leishmaniasis is found across South and Central America, Africa, Europe, the Middle-East and Asia, and generally it is classified into forms of the Old World and New World. Colombia now ranks second after Brazil, with around 15,000 reported cases per year. Most cases are caused by L. panamensis, L. braziliensis, and L. guyanensis. Since the 1940’s, Pentavalent antimonials (Sb5) parenteral treatment have been the first-line of drugs for treating cutaneous leishmaniasis, however, the cost, the variable efficacy and the toxicity associated with its use, make it necessary to search for new treatments. Although there are other approved treatments for the disease, They also show issues of adverse reactions, and are used is mainly as a second option of treatment depending on the availability of these in health programs. Topical therapy of cutaneous leishmaniasis is a promising approach. Anfoleish is a cream than developed in Colombia. In this paper, we report the results of phase Ib/II, randomized trial in Colombia to assess the safety and therapeutic response of topical Anfoleish for the treatment of Cutaneous leishmaniasis.

7 March 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LLLiliana López
Liliana López
BVBraulio Valencia
Braulio Valencia
FAFiorela Alvarez
Fiorela Alvarez
ATAna Pilar Ramos Ttito
Ana Pilar Ramos Ttito
ACAlejandro Llanos Cuentas
Alejandro Llanos Cuentas
BAByron Arana
Byron Arana
Systemic pentavalent antimonials, mainly meglumine antimoniate, continue to be the first-choice drugs for treatment of cutaneous leishmaniasis (CL) despite their toxicity, difficulty of administration and high cost. In the search for therapeutic alternatives, combining two treatment interventions has emerged as a potential alternative to either reduce the use of antimonials with the associated toxicities, or to increase efficacy. Here, we report the results of a recently completed trial assessing the efficacy and safety of a combination of thermotherapy (TT) plus a short course of miltefosine (MLT) for the treatment of uncomplicated CL in Colombia and Peru. A multicenter, randomized, evaluator-blinded, phase II, controled clinical trial was conducted. Adult volunteers with a parasitologically confirmed diagnosis of uncomplicated CL were randomly allocated to receive either a single session of TT or a combination of TT plus a short course of MLT (3 weeks). Therapeutic response outcomes and safety were assessed. 130 subjects were included in the study, of whom 64 were randomly assigned to the TT arm and 66 to the TT + MLT arm. Cure at 3 months’ follow-up was achieved in 57.8% (n = 37) and 80.3% (n = 53) in the TT and TT + MLT groups, respectively, in the intention to treat analysis. The TT + MLT regimen was better that TT alone (p = 0.0055). The presence of vesicles at the site of heat application was the most common adverse event reported associated with the use of TT; while vomiting (31.8%) and elevation of liver enzymes (28.8%) were the most frequent adverse events reported associated with the use of MLT. The combination of TT plus a short course of MLT was shown to be significantly better than TT alone for the treatment of uncomplicated CL in the New World. Registered in clinicaltrials.gov NCT02687971. Cutaneous leishmaniasis is a disease caused by Leishmania parasites transmitted by sandflies. It is a complex and neglected disease. Generally, it manifests as ulcers, nodules, or other lesions, mainly on the face and extremities. An estimated 0.7–1 million new cases occur annually in around 88 countries in South and Central America, Africa, Europe, the Middle East, and Asia, with the appearance of new outbreaks in different regions of the world. For more than 70 years, pentavalent antimonials have been the first line treatment, despite their toxicity, varying efficacy and need of administration of painful injections for 20 days or more. There is limited availability of effective and safe treatment alternatives and the strength of scientific evidence on the efficacy and safety of the different schemes is variable, limiting the control of the disease from a therapeutic approach. Hence the need for effective, safe, low-cost treatment alternatives with non-invasive routes of administration. This article reports the results of a clinical trial aiming to evaluate a combined therapy with two therapeutic alternatives (miltefosine and thermotherapy) approved for the treatment of cutaneous leishmaniasis, comparing it with thermotherapy alone. In this study, the combined therapy was significantly better than the monotherapy in managing cutaneous leishmaniasis.

10 March 2011 in Transfusion
Verified
Journal Article
Closed access
PDF file
LMLaureano Mestra
Laureano Mestra
LLLiliana Lopez
Liliana Lopez
SRSara M. Robledo
Sara M. Robledo
CMCarlos Muskus
Carlos Muskus
RNRubén S. Nicholls
Rubén S. Nicholls
IVIván Darío Vélez
Iván Darío Vélez

17 April 2018 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
LLLiliana López‐Carvajal
Liliana López‐Carvajal
IVIván Vélez
Iván Vélez
MAMaría Patricia Arbeláez
María Patricia Arbeláez
POPiero Olliaro
Piero Olliaro
Objective: To document the sources of heterogeneity in outcomes and shortcomings in trial designs reported by previous systematic reviews.Methods: Systematic review of clinical trials of CL treatments published since 1991, to assess and compare eligibility criteria and outcome measures in trials (any type of treatment) of CL (any form) reported before and after the publication of the CONSORT statement.Results: We identified 106 eligible trials published between 1991 and 2015, 74% after the 2001 CONSORT statement; 58% (n = 63) were on Old‐World CL and 37% (n = 40) in New‐World CL; overall, 11 531 patients enrolled in 243 treatment groups on 30 different treatments. Both requirements and definitions for eligibility and outcome criteria varied. Compliance with CONSORT requirements increased for studies published after the 2010 update. As for entry criteria, 94% of studies had a requirement for sex (74% of those enrolling also women excluded those who were pregnant or lactating), 69% for age (variable age ranges), 99% parasitological confirmation, 43% prior duration of illness (14% excluded cases with previous episodes), 46% defined the number, 28% the size and 13% the type of lesions (27% with restrictions as to their anatomical location). Follow‐up ranged 1–24 months, with 14% and 91% of studies, respectively, having defined initial and final cure.Conclusions: This review documents changes in reporting before and after the publication of the CONSORT statement. Lack of standardisation, compounded with the small number of trials relative to the magnitude of the disease in its multiple forms, and with the range of treatments tested explains why evidence to inform treatment guidelines is generally weak for CL. Adopting standardised methodologies will improve the quality and consistency of clinical trials, and ultimately yield better treatments for CL.

12 July 2023 in Asian Pacific Journal of Tropical Medicine
Verified
Journal Article
Open access
NMNicolás Rozo Montoya
Nicolás Rozo Montoya
JPJuliana Quintero Pulgarín
Juliana Quintero Pulgarín
LCLiliana López Carvajal
Liliana López Carvajal
Objective: To analyze the therapeutic response and safety of different treatments for cutaneous leishmaniasis, received by patients in the Program for the Study and Control of Tropical Diseases- PECET-Medellín-Colombia. Methods: This is a retrospective cross-sectional study of patients attended at PECET Research Center during 2016-2021. Relevant information regarding sociodemographic characteristics, history of leishmaniasis, characterization of current infection, treatment received, follow-up of therapeutic response and safety was collected from the medical records. Data were analyzed with Pearson's Chi-square association tests and Mann-Whitney U test using statistical software. Results: A total of 486 clinical records of patients were analyzed, and 356 received treatment. Eight different therapeutic alternatives (systemic, local and in combination) were analyzed. The therapeutic response of the different alternatives used (except thermotherapy) was higher than 50%. Most frequent adverse events were myalgias, arthralgias and headache, and vesicles for systemic and local treatment, respectively. Conclusions: Safety profile and performance of local therapeutic alternatives and combined schemes for the treatment of uncomplicated cutaneous leishmaniasis are an interesting option for the management of the disease.

22 May 2025 in Asian Pacific Journal of Tropical Medicine
Verified
Journal Article
Open access
SRSusana Ríos-Echavarría
Susana Ríos-Echavarría
JQJuliana Quintero-Pulgarín
Juliana Quintero-Pulgarín
CBClaudia Beltrán
Claudia Beltrán
LLLiliana López-Carvajal
Liliana López-Carvajal
Objective: To characterize the pediatric population with cutaneous leishmaniasis treated at a research center and to determine the therapeutic response and safety of the treatment. Methods: A cross-sectional study was designed, in which data related to sociodemographic information, history of leishmaniasis, clinical characteristics, treatment, therapeutic response and adverse events were collected from the review of the clinical records. Results: The analysis was conducted in 156 pediatric patients with median age of 10.5 (6-14) years. Regarding clinical and therapeutic characteristics, the lesions in these patients were mostly single ulcers, primarily located on the upper and lower extremities. A total of 114 patients were managed at Programa de Estudio y Control de Enfermedades Tropicales (PECET), and 26 of them received more than one treatment. Upon administration of the first therapeutic option, intralesional meglumine antimoniate had a cure rate of 43.18% (19/44 patients), followed by systemic meglumine antimoniate with a cure rate of 40% (8/20) and topical investigational medication with a cure rate of 25% (5/20). The most frequent adverse events were: arthralgia and myalgia for systemic meglumine antimoniate; nausea and vomiting for miltefosine; and local pain, edema, erythema and rash for topical treatment. Conclusions: Although more prospective studies are needed to generate evidence-based recommendations and management protocols, miltefosine appears to be a favorable, safe and well- tolerated therapeutic option for the pediatric population. Despite the high percentage of loss to follow-up, the success achieved in pediatric patients with local treatments suggests that local therapies could also be considered for managing this condition in this population.